NO310620B1 - Nye kinazolinforbindelser, farmasöytisk formulering inneholdende slike forbindelser, anvendelse derav, ogfremgangsmåte for deres fremstilling - Google Patents

Nye kinazolinforbindelser, farmasöytisk formulering inneholdende slike forbindelser, anvendelse derav, ogfremgangsmåte for deres fremstilling Download PDF

Info

Publication number
NO310620B1
NO310620B1 NO19981710A NO981710A NO310620B1 NO 310620 B1 NO310620 B1 NO 310620B1 NO 19981710 A NO19981710 A NO 19981710A NO 981710 A NO981710 A NO 981710A NO 310620 B1 NO310620 B1 NO 310620B1
Authority
NO
Norway
Prior art keywords
compound
formula
group
alkyl
quinazoline
Prior art date
Application number
NO19981710A
Other languages
English (en)
Norwegian (no)
Other versions
NO981710L (no
NO981710D0 (no
Inventor
Peter Richard John Hamley
Austen David Pimm
Alan Charles Tinker
Haydn Graham Beaton
Thomas Mcinally
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9521231.2A external-priority patent/GB9521231D0/en
Priority claimed from GBGB9602668.7A external-priority patent/GB9602668D0/en
Priority claimed from GBGB9614386.2A external-priority patent/GB9614386D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO981710D0 publication Critical patent/NO981710D0/no
Publication of NO981710L publication Critical patent/NO981710L/no
Publication of NO310620B1 publication Critical patent/NO310620B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO19981710A 1995-10-17 1998-04-16 Nye kinazolinforbindelser, farmasöytisk formulering inneholdende slike forbindelser, anvendelse derav, ogfremgangsmåte for deres fremstilling NO310620B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9521231.2A GB9521231D0 (en) 1995-10-17 1995-10-17 Pharmaceutically active compounds
GBGB9602668.7A GB9602668D0 (en) 1996-02-09 1996-02-09 Pharmaceutically active compounds
GBGB9614386.2A GB9614386D0 (en) 1996-07-09 1996-07-09 Pharmaceutically active compounds
PCT/GB1996/002496 WO1997014686A1 (en) 1995-10-17 1996-10-14 Pharmaceutically active quinazoline compounds

Publications (3)

Publication Number Publication Date
NO981710D0 NO981710D0 (no) 1998-04-16
NO981710L NO981710L (no) 1998-06-03
NO310620B1 true NO310620B1 (no) 2001-07-30

Family

ID=27267949

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19981710A NO310620B1 (no) 1995-10-17 1998-04-16 Nye kinazolinforbindelser, farmasöytisk formulering inneholdende slike forbindelser, anvendelse derav, ogfremgangsmåte for deres fremstilling

Country Status (20)

Country Link
US (1) US5883102A (de)
EP (1) EP0858451A1 (de)
JP (1) JPH11513679A (de)
KR (1) KR19990064276A (de)
CN (1) CN1204327A (de)
AR (1) AR004219A1 (de)
AU (1) AU704133B2 (de)
BR (1) BR9610988A (de)
CA (1) CA2235304A1 (de)
CZ (1) CZ119398A3 (de)
EE (1) EE9800116A (de)
HU (1) HUP9900028A3 (de)
IS (1) IS4715A (de)
NO (1) NO310620B1 (de)
NZ (1) NZ319673A (de)
PL (1) PL326353A1 (de)
SK (1) SK45898A3 (de)
TR (1) TR199800697T2 (de)
WO (1) WO1997014686A1 (de)
ZA (1) ZA968767B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9702534D0 (sv) * 1997-07-01 1997-07-01 Astra Pharma Prod Compounds
DE19731783A1 (de) * 1997-07-24 1999-01-28 Bayer Ag Verfahren zur Herstellung von N-(5-Amino-2-cyano-4-fluor-phenyl)-sulfonamiden und neue Zwischenprodukte
WO1999065494A1 (en) 1998-06-15 1999-12-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
SE9802333D0 (sv) 1998-06-29 1998-06-29 Astra Pharma Prod Novel combination
CA2342349A1 (en) * 1998-09-08 2000-03-16 Monsanto Company Methods of treating osteoarthritis with inducible nitric oxide synthase inhibitors
SE0000477D0 (sv) * 2000-02-14 2000-02-14 Astrazeneca Canada Inc Novel compounds
US6482829B2 (en) 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
US6534220B2 (en) 2000-12-29 2003-03-18 3M Innovative Properties Company High-boiling electrolyte solvent
AP1699A (en) * 2001-03-21 2006-12-26 Warner Lambert Co New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
US20040006111A1 (en) * 2002-01-25 2004-01-08 Kenneth Widder Transmucosal delivery of proton pump inhibitors
JP4613130B2 (ja) 2002-08-23 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ベンゾイミダゾールキノリノンおよびそれらの使用
WO2004022554A1 (en) * 2002-09-07 2004-03-18 Celltech R & D Limited Quinazolinone derivatives
US20040248942A1 (en) * 2003-02-20 2004-12-09 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
WO2005007115A2 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050031700A1 (en) * 2003-07-18 2005-02-10 Sanatarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
EP1735319B1 (de) * 2004-03-26 2017-05-03 MethylGene Inc. Histondeacetylase-hemmer
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2006122150A1 (en) * 2005-05-10 2006-11-16 Incyte Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
CN103936690B (zh) 2005-10-25 2016-06-08 盐野义制药株式会社 氨基二氢噻嗪衍生物
TW200804290A (en) * 2005-11-15 2008-01-16 Astrazeneca Ab Compounds and uses thereof
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
EP1971583B1 (de) 2005-12-20 2015-03-25 Incyte Corporation N-hydroxyamidinoheterocyclen als modulatoren der indolamin-2,3-dioxygenase
WO2007138613A2 (en) * 2006-05-25 2007-12-06 Vittal Mallya Scientific Research Foundation A process for synthesis of [6,7-bis-(2-methoxyethoxy)-quinazolin-4-yl]-(3-ethynylphenyl)amine hydrochloride
WO2007138612A2 (en) * 2006-05-25 2007-12-06 Vittal Mallya Scientific Research Foundation A process for synthesis of [6,7-bis-(2-methoxyethoxy)-quinazolin-4- yl]-(3-ethynylphenyl)amine hydrochloride
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
JP5319532B2 (ja) 2006-09-19 2013-10-16 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
JP5383483B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
EP2147914B1 (de) 2007-04-24 2014-06-04 Shionogi&Co., Ltd. Mit zyklischen gruppen substituierte aminodihydrothiazin-derivate
DE102007038250A1 (de) * 2007-08-13 2009-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neues Herstellverfahren
ES2738123T3 (es) 2008-06-13 2020-01-20 Shionogi & Co Derivado heterocíclico que contiene azufre que tiene actividad inhibitoria de ß-secretasa
LT2824100T (lt) 2008-07-08 2018-05-10 Incyte Holdings Corporation 1,2,5-oksadiazolai, kaip indolamino 2,3-dioksigenazės inhibitoriai
JPWO2010047372A1 (ja) 2008-10-22 2012-03-22 塩野義製薬株式会社 Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体
BR112012013854A2 (pt) 2009-12-11 2019-09-24 Shionogi & Co derivados de oxazina.
US20120258961A1 (en) * 2009-12-24 2012-10-11 Shionogi & Co., Ltd. 4-amino-1,3-thiazine or oxazine derivative
JP5766198B2 (ja) 2010-10-29 2015-08-19 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
US8927721B2 (en) 2010-10-29 2015-01-06 Shionogi & Co., Ltd. Naphthyridine derivative
US8883779B2 (en) 2011-04-26 2014-11-11 Shinogi & Co., Ltd. Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them
UA111854C2 (uk) * 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
KR101699822B1 (ko) * 2011-12-21 2017-01-25 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
WO2014065434A1 (en) 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
AR098343A1 (es) 2013-11-08 2016-05-26 Incyte Holdings Corp Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa

Also Published As

Publication number Publication date
NO981710L (no) 1998-06-03
BR9610988A (pt) 1999-04-06
CZ119398A3 (cs) 1998-09-16
ZA968767B (en) 1997-04-17
HUP9900028A3 (en) 1999-11-29
AU704133B2 (en) 1999-04-15
JPH11513679A (ja) 1999-11-24
CN1204327A (zh) 1999-01-06
NZ319673A (en) 2000-06-23
SK45898A3 (en) 1999-01-11
US5883102A (en) 1999-03-16
CA2235304A1 (en) 1997-04-24
PL326353A1 (en) 1998-09-14
EE9800116A (et) 1998-10-15
WO1997014686A1 (en) 1997-04-24
EP0858451A1 (de) 1998-08-19
IS4715A (is) 1998-04-15
TR199800697T2 (xx) 1998-07-21
AR004219A1 (es) 1998-11-04
AU7224396A (en) 1997-05-07
KR19990064276A (ko) 1999-07-26
MX9802926A (de) 1998-08-01
HUP9900028A2 (hu) 1999-04-28
NO981710D0 (no) 1998-04-16

Similar Documents

Publication Publication Date Title
NO310620B1 (no) Nye kinazolinforbindelser, farmasöytisk formulering inneholdende slike forbindelser, anvendelse derav, ogfremgangsmåte for deres fremstilling
AU2009320683B2 (en) Pyridine-3-carboxyamide derivative
CA2646678C (en) Cyclohexylimidazole lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
US6965036B2 (en) Intermediates for guanidine mimics as factor Xa inhibitors
JP4394442B2 (ja) 抗炎症剤として有用なスピロ−ヒダントイン化合物
CA2647677C (en) Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
DE69921358T2 (de) Stickstoffhaltige heterobicyclen als faktor-xa-hemmer
JP4422800B2 (ja) 心臓循環系疾患の処置のための新規な置換ピラゾール誘導体
AU2007292155B2 (en) Imidazole derivative
JP6601818B2 (ja) ポリエンマクロライド誘導体
HRP20020327A2 (en) Alkylamino substited bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
SK48799A3 (en) New heterocyclylmethyl-substituted pyrazol derivates and their use for treating cardiovascular diseases
CA2961186A1 (en) Tricyclic derivative
CN110997661A (zh) 环丙基脲甲酰肽2受体和甲酰肽1受体激动剂
JP2011516398A (ja) Ｎｐｙ−ｙ５アンタゴニストとしてのヘテロスピロ−デカン残基を有するベンズイミダゾール誘導体
AU2004212435A1 (en) Process for preparing pyrrolotriazine kinase inhibitors
CZ327698A3 (cs) Aminoisochinolinový a aminothienopyridinový derivát a jejich použití jako protizánětlivých přípravků
MX2013005773A (es) Inhibidores de kat ii.
KR20010006143A (ko) 화합물
AU2004200420A1 (en) Inhibitor of cyclooxygenase
MXPA98002926A (en) Pharmaceutically active quinazoline compounds
NO874780L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolo-benzimidazol-derivater.
WO2024180520A1 (en) Novel atx inhibitors
US20080167302A1 (en) Peptide Deformylase Inhibitors
AU2002334771A1 (en) Spiro-hydantoin compounds useful as anti-inflammatory agents

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN APRIL 2003